Skip to main content
Premium Trial:

Request an Annual Quote

Pressure BioSciences Sells Remaining Stake in Source Scientific

NEW YORK (GenomeWeb News) — Pressure BioSciences today said it has received $1.8 million for selling its Source Scientific subsidiary to two individuals, Richard Henson and Bruce Sargeant.
PBI had originally received $1.2 million, which comprised a repayment of aggregate principal and promissory notes stemming from a 2004 agreement under which Sargeant and Henson bought 70 percent of Source Scientific.
The remaining $580,000 covered the final 30 percent of PBI’s ownership in the company and included an escalating premium of between 10 percent and 50 percent, PBI said.
PBI created Source Scientific when it transferred some of its assets into an LLC as part of an effort to begin divesting from the lab-instruments business.
The company said that Source Scientific has “entered into a new, working relationship” with the German contract manufacturing company BIT Analytical Instruments.
PBI’s senior vice president and CFO Edward Myles said the company plans to use the cash to support commercialization costs associated with its PCT, or pressure cycling technology.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.